nodes	percent_of_prediction	percent_of_DWPC	metapath
Gonadorelin—Degarelix—prostate cancer	0.234	0.601	CrCtD
Gonadorelin—GNRHR—Degarelix—prostate cancer	0.188	0.635	CbGbCtD
Gonadorelin—Goserelin—prostate cancer	0.155	0.398	CrCtD
Gonadorelin—GNRHR—Goserelin—prostate cancer	0.108	0.365	CbGbCtD
Gonadorelin—Icatibant—Goserelin—prostate cancer	0.0469	0.179	CrCrCtD
Gonadorelin—Cetrorelix—Degarelix—prostate cancer	0.034	0.13	CrCrCtD
Gonadorelin—Ceruletide—Degarelix—prostate cancer	0.0294	0.112	CrCrCtD
Gonadorelin—Goserelin—Degarelix—prostate cancer	0.026	0.0991	CrCrCtD
Gonadorelin—Nafarelin—Degarelix—prostate cancer	0.0233	0.0891	CrCrCtD
Gonadorelin—Cetrorelix—Goserelin—prostate cancer	0.0225	0.0859	CrCrCtD
Gonadorelin—Degarelix—Goserelin—prostate cancer	0.0225	0.0859	CrCrCtD
Gonadorelin—Pentagastrin—Goserelin—prostate cancer	0.0225	0.0859	CrCrCtD
Gonadorelin—Ceruletide—Goserelin—prostate cancer	0.0195	0.0743	CrCrCtD
Gonadorelin—Nafarelin—Goserelin—prostate cancer	0.0155	0.059	CrCrCtD
Gonadorelin—GNRHR—Hormone ligand-binding receptors—GNRH1—prostate cancer	0.00124	0.132	CbGpPWpGaD
Gonadorelin—GNRHR—Peptide GPCRs—GRPR—prostate cancer	0.000403	0.0429	CbGpPWpGaD
Gonadorelin—GNRHR—GPCRs, Other—GRPR—prostate cancer	0.000342	0.0363	CbGpPWpGaD
Gonadorelin—GNRHR—Peptide GPCRs—MC2R—prostate cancer	0.000331	0.0352	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—GRPR—prostate cancer	0.000192	0.0204	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GRPR—prostate cancer	0.000172	0.0183	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—RLN2—prostate cancer	0.000145	0.0154	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—GRPR—prostate cancer	0.000127	0.0135	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—GNRH1—prostate cancer	0.00012	0.0127	CbGpPWpGaD
Gonadorelin—GNRHR—GPCRs, Other—ADRB2—prostate cancer	0.000119	0.0126	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—LPAR1—prostate cancer	0.000116	0.0123	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—GRP—prostate cancer	0.000116	0.0123	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—PLCB2—prostate cancer	0.000115	0.0122	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—RLN2—prostate cancer	0.00011	0.0117	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—prostate cancer	0.000107	0.0114	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—MC2R—prostate cancer	0.000104	0.0111	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—GNG5—prostate cancer	0.000104	0.0111	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—prostate cancer	0.000104	0.011	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—LPAR1—prostate cancer	0.000104	0.011	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PLCB2—prostate cancer	0.000103	0.0109	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—GRPR—prostate cancer	9.69e-05	0.0103	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—PENK—prostate cancer	9.31e-05	0.00989	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GNG5—prostate cancer	9.3e-05	0.00988	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—ANXA1—prostate cancer	8.52e-05	0.00905	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—WNT4—prostate cancer	8.34e-05	0.00886	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—OR51E2—prostate cancer	8.21e-05	0.00872	CbGpPWpGaD
Gonadorelin—Redness—Doxorubicin—prostate cancer	7.97e-05	0.00182	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—MC2R—prostate cancer	7.96e-05	0.00845	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—GNRH1—prostate cancer	7.92e-05	0.00841	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Degarelix—prostate cancer	7.89e-05	0.0018	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Estradiol—prostate cancer	7.8e-05	0.00178	CcSEcCtD
Gonadorelin—Angiopathy—Goserelin—prostate cancer	7.69e-05	0.00175	CcSEcCtD
Gonadorelin—Asthenia—Degarelix—prostate cancer	7.69e-05	0.00175	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—LPAR1—prostate cancer	7.67e-05	0.00815	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—GRP—prostate cancer	7.67e-05	0.00815	CbGpPWpGaD
Gonadorelin—Nausea—Estrone—prostate cancer	7.67e-05	0.00175	CcSEcCtD
Gonadorelin—Immune system disorder—Goserelin—prostate cancer	7.66e-05	0.00175	CcSEcCtD
Gonadorelin—Vomiting—Nilutamide—prostate cancer	7.62e-05	0.00174	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—prostate cancer	7.62e-05	0.0081	CbGpPWpGaD
Gonadorelin—Angiopathy—Conjugated Estrogens—prostate cancer	7.62e-05	0.00174	CcSEcCtD
Gonadorelin—Vomiting—Flutamide—prostate cancer	7.59e-05	0.00173	CcSEcCtD
Gonadorelin—Immune system disorder—Conjugated Estrogens—prostate cancer	7.58e-05	0.00173	CcSEcCtD
Gonadorelin—Pruritus—Degarelix—prostate cancer	7.58e-05	0.00173	CcSEcCtD
Gonadorelin—Headache—Nilutamide—prostate cancer	7.51e-05	0.00171	CcSEcCtD
Gonadorelin—Headache—Flutamide—prostate cancer	7.48e-05	0.00171	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Bicalutamide—prostate cancer	7.47e-05	0.0017	CcSEcCtD
Gonadorelin—Fatigue—Bicalutamide—prostate cancer	7.46e-05	0.0017	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—OR51E2—prostate cancer	7.45e-05	0.00792	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CX3CL1—prostate cancer	7.45e-05	0.00791	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Cabazitaxel—prostate cancer	7.44e-05	0.0017	CcSEcCtD
Gonadorelin—Pain—Bicalutamide—prostate cancer	7.4e-05	0.00169	CcSEcCtD
Gonadorelin—Constipation—Bicalutamide—prostate cancer	7.4e-05	0.00169	CcSEcCtD
Gonadorelin—Erythema—Goserelin—prostate cancer	7.38e-05	0.00168	CcSEcCtD
Gonadorelin—Diarrhoea—Degarelix—prostate cancer	7.33e-05	0.00167	CcSEcCtD
Gonadorelin—Erythema—Conjugated Estrogens—prostate cancer	7.31e-05	0.00167	CcSEcCtD
Gonadorelin—Flatulence—Goserelin—prostate cancer	7.27e-05	0.00166	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Mitoxantrone—prostate cancer	7.27e-05	0.00166	CcSEcCtD
Gonadorelin—Asthenia—Cabazitaxel—prostate cancer	7.24e-05	0.00165	CcSEcCtD
Gonadorelin—Flatulence—Conjugated Estrogens—prostate cancer	7.2e-05	0.00164	CcSEcCtD
Gonadorelin—Nervous system disorder—Ethinyl Estradiol—prostate cancer	7.18e-05	0.00164	CcSEcCtD
Gonadorelin—Vomiting—Estradiol valerate/Dienogest—prostate cancer	7.16e-05	0.00163	CcSEcCtD
Gonadorelin—Nausea—Nilutamide—prostate cancer	7.12e-05	0.00162	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—PRKCQ—prostate cancer	7.11e-05	0.00755	CbGpPWpGaD
Gonadorelin—Swelling—Docetaxel—prostate cancer	7.09e-05	0.00162	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—PENK—prostate cancer	7.09e-05	0.00753	CbGpPWpGaD
Gonadorelin—Nausea—Flutamide—prostate cancer	7.09e-05	0.00162	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Bicalutamide—prostate cancer	7.08e-05	0.00161	CcSEcCtD
Gonadorelin—Headache—Estradiol valerate/Dienogest—prostate cancer	7.06e-05	0.00161	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—RGS17—prostate cancer	6.98e-05	0.00741	CbGpPWpGaD
Gonadorelin—Diarrhoea—Cabazitaxel—prostate cancer	6.9e-05	0.00157	CcSEcCtD
Gonadorelin—Swelling—Capecitabine—prostate cancer	6.87e-05	0.00157	CcSEcCtD
Gonadorelin—Abdominal pain—Bicalutamide—prostate cancer	6.84e-05	0.00156	CcSEcCtD
Gonadorelin—Vomiting—Degarelix—prostate cancer	6.81e-05	0.00155	CcSEcCtD
Gonadorelin—Headache—Degarelix—prostate cancer	6.71e-05	0.00153	CcSEcCtD
Gonadorelin—Nausea—Estradiol valerate/Dienogest—prostate cancer	6.69e-05	0.00153	CcSEcCtD
Gonadorelin—Breast pain—Epirubicin—prostate cancer	6.66e-05	0.00152	CcSEcCtD
Gonadorelin—Vomiting—Cabazitaxel—prostate cancer	6.42e-05	0.00146	CcSEcCtD
Gonadorelin—Hypersensitivity—Bicalutamide—prostate cancer	6.38e-05	0.00145	CcSEcCtD
Gonadorelin—Nausea—Degarelix—prostate cancer	6.36e-05	0.00145	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCQ—prostate cancer	6.36e-05	0.00676	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—RGS17—prostate cancer	6.34e-05	0.00673	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—ITPR1—prostate cancer	6.32e-05	0.00672	CbGpPWpGaD
Gonadorelin—Headache—Cabazitaxel—prostate cancer	6.32e-05	0.00144	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Ethinyl Estradiol—prostate cancer	6.32e-05	0.00144	CcSEcCtD
Gonadorelin—Fatigue—Ethinyl Estradiol—prostate cancer	6.31e-05	0.00144	CcSEcCtD
Gonadorelin—Constipation—Ethinyl Estradiol—prostate cancer	6.26e-05	0.00143	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—RLN2—prostate cancer	6.22e-05	0.00661	CbGpPWpGaD
Gonadorelin—Asthenia—Bicalutamide—prostate cancer	6.21e-05	0.00142	CcSEcCtD
Gonadorelin—Breast pain—Doxorubicin—prostate cancer	6.17e-05	0.00141	CcSEcCtD
Gonadorelin—Pruritus—Bicalutamide—prostate cancer	6.13e-05	0.0014	CcSEcCtD
Gonadorelin—Angiopathy—Estradiol—prostate cancer	6.1e-05	0.00139	CcSEcCtD
Gonadorelin—Immune system disorder—Estradiol—prostate cancer	6.07e-05	0.00138	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—GNRH1—prostate cancer	6.03e-05	0.00641	CbGpPWpGaD
Gonadorelin—Anaphylactic shock—Goserelin—prostate cancer	6.02e-05	0.00137	CcSEcCtD
Gonadorelin—Nausea—Cabazitaxel—prostate cancer	5.99e-05	0.00137	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Ethinyl Estradiol—prostate cancer	5.98e-05	0.00136	CcSEcCtD
Gonadorelin—Anaphylactic shock—Conjugated Estrogens—prostate cancer	5.97e-05	0.00136	CcSEcCtD
Gonadorelin—Shock—Goserelin—prostate cancer	5.93e-05	0.00135	CcSEcCtD
Gonadorelin—Diarrhoea—Bicalutamide—prostate cancer	5.92e-05	0.00135	CcSEcCtD
Gonadorelin—Nervous system disorder—Goserelin—prostate cancer	5.91e-05	0.00135	CcSEcCtD
Gonadorelin—Shock—Conjugated Estrogens—prostate cancer	5.87e-05	0.00134	CcSEcCtD
Gonadorelin—Nervous system disorder—Conjugated Estrogens—prostate cancer	5.85e-05	0.00133	CcSEcCtD
Gonadorelin—Erythema—Estradiol—prostate cancer	5.85e-05	0.00133	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—LPAR1—prostate cancer	5.84e-05	0.0062	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—GRP—prostate cancer	5.84e-05	0.0062	CbGpPWpGaD
Gonadorelin—Abdominal pain—Ethinyl Estradiol—prostate cancer	5.78e-05	0.00132	CcSEcCtD
Gonadorelin—Injection site reaction—Epirubicin—prostate cancer	5.78e-05	0.00132	CcSEcCtD
Gonadorelin—Flatulence—Estradiol—prostate cancer	5.76e-05	0.00131	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—PLXNB1—prostate cancer	5.69e-05	0.00604	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CX3CL1—prostate cancer	5.67e-05	0.00602	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR1—prostate cancer	5.66e-05	0.00601	CbGpPWpGaD
Gonadorelin—Breast disorder—Docetaxel—prostate cancer	5.65e-05	0.00129	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—RLN2—prostate cancer	5.65e-05	0.006	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ANXA1—prostate cancer	5.64e-05	0.00599	CbGpPWpGaD
Gonadorelin—Vomiting—Bicalutamide—prostate cancer	5.5e-05	0.00126	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—GRPR—prostate cancer	5.48e-05	0.00582	CbGpPWpGaD
Gonadorelin—Breast disorder—Capecitabine—prostate cancer	5.47e-05	0.00125	CcSEcCtD
Gonadorelin—Erythema—Mitoxantrone—prostate cancer	5.45e-05	0.00124	CcSEcCtD
Gonadorelin—Headache—Bicalutamide—prostate cancer	5.42e-05	0.00124	CcSEcCtD
Gonadorelin—Hypersensitivity—Ethinyl Estradiol—prostate cancer	5.39e-05	0.00123	CcSEcCtD
Gonadorelin—Injection site reaction—Doxorubicin—prostate cancer	5.35e-05	0.00122	CcSEcCtD
Gonadorelin—Asthenia—Ethinyl Estradiol—prostate cancer	5.25e-05	0.0012	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—GNG5—prostate cancer	5.25e-05	0.00557	CbGpPWpGaD
Gonadorelin—Fatigue—Goserelin—prostate cancer	5.19e-05	0.00118	CcSEcCtD
Gonadorelin—Pruritus—Ethinyl Estradiol—prostate cancer	5.18e-05	0.00118	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—PLXNB1—prostate cancer	5.17e-05	0.00549	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL12—prostate cancer	5.16e-05	0.00548	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	5.15e-05	0.00117	CcSEcCtD
Gonadorelin—Constipation—Goserelin—prostate cancer	5.15e-05	0.00117	CcSEcCtD
Gonadorelin—Pain—Goserelin—prostate cancer	5.15e-05	0.00117	CcSEcCtD
Gonadorelin—Fatigue—Conjugated Estrogens—prostate cancer	5.14e-05	0.00117	CcSEcCtD
Gonadorelin—Nausea—Bicalutamide—prostate cancer	5.14e-05	0.00117	CcSEcCtD
Gonadorelin—Constipation—Conjugated Estrogens—prostate cancer	5.1e-05	0.00116	CcSEcCtD
Gonadorelin—Pain—Conjugated Estrogens—prostate cancer	5.1e-05	0.00116	CcSEcCtD
Gonadorelin—Abdominal discomfort—Capecitabine—prostate cancer	5.02e-05	0.00114	CcSEcCtD
Gonadorelin—Diarrhoea—Ethinyl Estradiol—prostate cancer	5.01e-05	0.00114	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—GRPR—prostate cancer	4.97e-05	0.00528	CbGpPWpGaD
Gonadorelin—Gastrointestinal pain—Goserelin—prostate cancer	4.92e-05	0.00112	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	4.88e-05	0.00111	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Capecitabine—prostate cancer	4.87e-05	0.00111	CcSEcCtD
Gonadorelin—Anaphylactic shock—Estradiol—prostate cancer	4.77e-05	0.00109	CcSEcCtD
Gonadorelin—Abdominal pain—Goserelin—prostate cancer	4.76e-05	0.00109	CcSEcCtD
Gonadorelin—Angiopathy—Etoposide—prostate cancer	4.73e-05	0.00108	CcSEcCtD
Gonadorelin—Abdominal pain—Conjugated Estrogens—prostate cancer	4.72e-05	0.00108	CcSEcCtD
Gonadorelin—Immune system disorder—Etoposide—prostate cancer	4.7e-05	0.00107	CcSEcCtD
Gonadorelin—Shock—Estradiol—prostate cancer	4.7e-05	0.00107	CcSEcCtD
Gonadorelin—Nervous system disorder—Estradiol—prostate cancer	4.68e-05	0.00107	CcSEcCtD
Gonadorelin—Vomiting—Ethinyl Estradiol—prostate cancer	4.65e-05	0.00106	CcSEcCtD
Gonadorelin—Headache—Ethinyl Estradiol—prostate cancer	4.58e-05	0.00105	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—PTHLH—prostate cancer	4.57e-05	0.00486	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—MC2R—prostate cancer	4.5e-05	0.00478	CbGpPWpGaD
Gonadorelin—Anaphylactic shock—Mitoxantrone—prostate cancer	4.45e-05	0.00101	CcSEcCtD
Gonadorelin—Hypersensitivity—Goserelin—prostate cancer	4.44e-05	0.00101	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ADRB2—prostate cancer	4.43e-05	0.0047	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—OR51E2—prostate cancer	4.4e-05	0.00468	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Conjugated Estrogens—prostate cancer	4.4e-05	0.001	CcSEcCtD
Gonadorelin—Shock—Mitoxantrone—prostate cancer	4.38e-05	0.000998	CcSEcCtD
Gonadorelin—Nausea—Ethinyl Estradiol—prostate cancer	4.35e-05	0.000991	CcSEcCtD
Gonadorelin—Asthenia—Goserelin—prostate cancer	4.32e-05	0.000985	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—ANXA1—prostate cancer	4.3e-05	0.00456	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—WNT4—prostate cancer	4.28e-05	0.00455	CbGpPWpGaD
Gonadorelin—Asthenia—Conjugated Estrogens—prostate cancer	4.28e-05	0.000976	CcSEcCtD
Gonadorelin—Pruritus—Goserelin—prostate cancer	4.26e-05	0.000972	CcSEcCtD
Gonadorelin—Pruritus—Conjugated Estrogens—prostate cancer	4.22e-05	0.000962	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Estradiol—prostate cancer	4.12e-05	0.00094	CcSEcCtD
Gonadorelin—Diarrhoea—Goserelin—prostate cancer	4.12e-05	0.00094	CcSEcCtD
Gonadorelin—Fatigue—Estradiol—prostate cancer	4.12e-05	0.000939	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—MC2R—prostate cancer	4.08e-05	0.00434	CbGpPWpGaD
Gonadorelin—Pain—Estradiol—prostate cancer	4.08e-05	0.000931	CcSEcCtD
Gonadorelin—Constipation—Estradiol—prostate cancer	4.08e-05	0.000931	CcSEcCtD
Gonadorelin—Diarrhoea—Conjugated Estrogens—prostate cancer	4.08e-05	0.000931	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—BMPR1B—prostate cancer	4.03e-05	0.00428	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CALCA—prostate cancer	4.02e-05	0.00427	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PENK—prostate cancer	4.01e-05	0.00426	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CXCL12—prostate cancer	3.93e-05	0.00418	CbGpPWpGaD
Gonadorelin—Angiopathy—Docetaxel—prostate cancer	3.93e-05	0.000896	CcSEcCtD
Gonadorelin—Immune system disorder—Docetaxel—prostate cancer	3.91e-05	0.000892	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Estradiol—prostate cancer	3.9e-05	0.00089	CcSEcCtD
Gonadorelin—Fatigue—Mitoxantrone—prostate cancer	3.84e-05	0.000875	CcSEcCtD
Gonadorelin—Vomiting—Goserelin—prostate cancer	3.83e-05	0.000873	CcSEcCtD
Gonadorelin—Breast disorder—Epirubicin—prostate cancer	3.81e-05	0.00087	CcSEcCtD
Gonadorelin—Pain—Mitoxantrone—prostate cancer	3.8e-05	0.000867	CcSEcCtD
Gonadorelin—Constipation—Mitoxantrone—prostate cancer	3.8e-05	0.000867	CcSEcCtD
Gonadorelin—Angiopathy—Capecitabine—prostate cancer	3.8e-05	0.000867	CcSEcCtD
Gonadorelin—Vomiting—Conjugated Estrogens—prostate cancer	3.79e-05	0.000865	CcSEcCtD
Gonadorelin—Immune system disorder—Capecitabine—prostate cancer	3.79e-05	0.000863	CcSEcCtD
Gonadorelin—Abdominal pain—Estradiol—prostate cancer	3.77e-05	0.000861	CcSEcCtD
Gonadorelin—Headache—Goserelin—prostate cancer	3.77e-05	0.00086	CcSEcCtD
Gonadorelin—Erythema—Docetaxel—prostate cancer	3.77e-05	0.000859	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—RGS17—prostate cancer	3.74e-05	0.00398	CbGpPWpGaD
Gonadorelin—Headache—Conjugated Estrogens—prostate cancer	3.74e-05	0.000852	CcSEcCtD
Gonadorelin—Anaphylactic shock—Etoposide—prostate cancer	3.7e-05	0.000844	CcSEcCtD
Gonadorelin—Erythema—Capecitabine—prostate cancer	3.65e-05	0.000832	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—PENK—prostate cancer	3.64e-05	0.00387	CbGpPWpGaD
Gonadorelin—Gastrointestinal pain—Mitoxantrone—prostate cancer	3.64e-05	0.00083	CcSEcCtD
Gonadorelin—Flatulence—Capecitabine—prostate cancer	3.59e-05	0.00082	CcSEcCtD
Gonadorelin—Nausea—Goserelin—prostate cancer	3.58e-05	0.000816	CcSEcCtD
Gonadorelin—Nausea—Conjugated Estrogens—prostate cancer	3.54e-05	0.000808	CcSEcCtD
Gonadorelin—Breast disorder—Doxorubicin—prostate cancer	3.53e-05	0.000805	CcSEcCtD
Gonadorelin—Hypersensitivity—Estradiol—prostate cancer	3.52e-05	0.000802	CcSEcCtD
Gonadorelin—Abdominal pain—Mitoxantrone—prostate cancer	3.52e-05	0.000802	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—prostate cancer	3.47e-05	0.00369	CbGpPWpGaD
Gonadorelin—Asthenia—Estradiol—prostate cancer	3.43e-05	0.000781	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—GNRH1—prostate cancer	3.41e-05	0.00362	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—VIP—prostate cancer	3.41e-05	0.00362	CbGpPWpGaD
Gonadorelin—Upper respiratory tract infection—Epirubicin—prostate cancer	3.39e-05	0.000773	CcSEcCtD
Gonadorelin—Angiopathy—Prednisone—prostate cancer	3.39e-05	0.000772	CcSEcCtD
Gonadorelin—Pruritus—Estradiol—prostate cancer	3.38e-05	0.00077	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—ADRB2—prostate cancer	3.37e-05	0.00358	CbGpPWpGaD
Gonadorelin—Immune system disorder—Prednisone—prostate cancer	3.37e-05	0.000769	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—RLN2—prostate cancer	3.34e-05	0.00354	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—GRP—prostate cancer	3.3e-05	0.00351	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—LPAR1—prostate cancer	3.3e-05	0.00351	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Mitoxantrone—prostate cancer	3.28e-05	0.000747	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—PLCB2—prostate cancer	3.27e-05	0.00347	CbGpPWpGaD
Gonadorelin—Diarrhoea—Estradiol—prostate cancer	3.27e-05	0.000745	CcSEcCtD
Gonadorelin—Erythema—Prednisone—prostate cancer	3.25e-05	0.000741	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Etoposide—prostate cancer	3.19e-05	0.000728	CcSEcCtD
Gonadorelin—Asthenia—Mitoxantrone—prostate cancer	3.19e-05	0.000728	CcSEcCtD
Gonadorelin—Fatigue—Etoposide—prostate cancer	3.19e-05	0.000727	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—CTBP2—prostate cancer	3.18e-05	0.00338	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HSD17B1—prostate cancer	3.18e-05	0.00338	CbGpPWpGaD
Gonadorelin—Constipation—Etoposide—prostate cancer	3.16e-05	0.000722	CcSEcCtD
Gonadorelin—Pain—Etoposide—prostate cancer	3.16e-05	0.000722	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—prostate cancer	3.16e-05	0.00336	CbGpPWpGaD
Gonadorelin—Upper respiratory tract infection—Doxorubicin—prostate cancer	3.14e-05	0.000715	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—PDE4D—prostate cancer	3.12e-05	0.00331	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—GNRH1—prostate cancer	3.09e-05	0.00329	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—VIP—prostate cancer	3.09e-05	0.00329	CbGpPWpGaD
Gonadorelin—Anaphylactic shock—Docetaxel—prostate cancer	3.08e-05	0.000701	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—PLXNB1—prostate cancer	3.05e-05	0.00324	CbGpPWpGaD
Gonadorelin—Diarrhoea—Mitoxantrone—prostate cancer	3.04e-05	0.000694	CcSEcCtD
Gonadorelin—Vomiting—Estradiol—prostate cancer	3.04e-05	0.000692	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Etoposide—prostate cancer	3.03e-05	0.00069	CcSEcCtD
Gonadorelin—Shock—Docetaxel—prostate cancer	3.03e-05	0.00069	CcSEcCtD
Gonadorelin—Nervous system disorder—Docetaxel—prostate cancer	3.02e-05	0.000688	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—GRP—prostate cancer	3e-05	0.00318	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—LPAR1—prostate cancer	3e-05	0.00318	CbGpPWpGaD
Gonadorelin—Headache—Estradiol—prostate cancer	2.99e-05	0.000682	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—PLCB2—prostate cancer	2.97e-05	0.00315	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—GNG5—prostate cancer	2.96e-05	0.00315	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GRPR—prostate cancer	2.94e-05	0.00312	CbGpPWpGaD
Gonadorelin—Shock—Capecitabine—prostate cancer	2.93e-05	0.000668	CcSEcCtD
Gonadorelin—Abdominal pain—Etoposide—prostate cancer	2.93e-05	0.000667	CcSEcCtD
Gonadorelin—Nervous system disorder—Capecitabine—prostate cancer	2.92e-05	0.000666	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—CX3CL1—prostate cancer	2.91e-05	0.00309	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IL17RD—prostate cancer	2.84e-05	0.00301	CbGpPWpGaD
Gonadorelin—Nausea—Estradiol—prostate cancer	2.84e-05	0.000647	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—PDE4D—prostate cancer	2.83e-05	0.00301	CbGpPWpGaD
Gonadorelin—Vomiting—Mitoxantrone—prostate cancer	2.83e-05	0.000645	CcSEcCtD
Gonadorelin—Headache—Mitoxantrone—prostate cancer	2.79e-05	0.000636	CcSEcCtD
Gonadorelin—Hypersensitivity—Etoposide—prostate cancer	2.73e-05	0.000622	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—GNG5—prostate cancer	2.69e-05	0.00286	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Docetaxel—prostate cancer	2.65e-05	0.000605	CcSEcCtD
Gonadorelin—Asthenia—Etoposide—prostate cancer	2.65e-05	0.000605	CcSEcCtD
Gonadorelin—Anaphylactic shock—Prednisone—prostate cancer	2.65e-05	0.000605	CcSEcCtD
Gonadorelin—Fatigue—Docetaxel—prostate cancer	2.65e-05	0.000605	CcSEcCtD
Gonadorelin—Angiopathy—Epirubicin—prostate cancer	2.65e-05	0.000604	CcSEcCtD
Gonadorelin—Nausea—Mitoxantrone—prostate cancer	2.64e-05	0.000603	CcSEcCtD
Gonadorelin—Immune system disorder—Epirubicin—prostate cancer	2.64e-05	0.000601	CcSEcCtD
Gonadorelin—Pain—Docetaxel—prostate cancer	2.63e-05	0.0006	CcSEcCtD
Gonadorelin—Constipation—Docetaxel—prostate cancer	2.63e-05	0.0006	CcSEcCtD
Gonadorelin—Pruritus—Etoposide—prostate cancer	2.62e-05	0.000597	CcSEcCtD
Gonadorelin—Shock—Prednisone—prostate cancer	2.61e-05	0.000595	CcSEcCtD
Gonadorelin—Nervous system disorder—Prednisone—prostate cancer	2.6e-05	0.000593	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—PTHLH—prostate cancer	2.58e-05	0.00274	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Capecitabine—prostate cancer	2.57e-05	0.000586	CcSEcCtD
Gonadorelin—Fatigue—Capecitabine—prostate cancer	2.57e-05	0.000585	CcSEcCtD
Gonadorelin—Pain—Capecitabine—prostate cancer	2.55e-05	0.000581	CcSEcCtD
Gonadorelin—Constipation—Capecitabine—prostate cancer	2.55e-05	0.000581	CcSEcCtD
Gonadorelin—Erythema—Epirubicin—prostate cancer	2.54e-05	0.00058	CcSEcCtD
Gonadorelin—Diarrhoea—Etoposide—prostate cancer	2.53e-05	0.000577	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—JUP—prostate cancer	2.53e-05	0.00269	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—WNT4—prostate cancer	2.53e-05	0.00269	CbGpPWpGaD
Gonadorelin—Gastrointestinal pain—Docetaxel—prostate cancer	2.51e-05	0.000573	CcSEcCtD
Gonadorelin—Flatulence—Epirubicin—prostate cancer	2.5e-05	0.000571	CcSEcCtD
Gonadorelin—Angiopathy—Doxorubicin—prostate cancer	2.45e-05	0.000559	CcSEcCtD
Gonadorelin—Immune system disorder—Doxorubicin—prostate cancer	2.44e-05	0.000556	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Capecitabine—prostate cancer	2.43e-05	0.000555	CcSEcCtD
Gonadorelin—Abdominal pain—Docetaxel—prostate cancer	2.43e-05	0.000554	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—ANXA1—prostate cancer	2.43e-05	0.00258	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MC2R—prostate cancer	2.41e-05	0.00256	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—RALBP1—prostate cancer	2.41e-05	0.00256	CbGpPWpGaD
Gonadorelin—Abdominal pain—Capecitabine—prostate cancer	2.35e-05	0.000537	CcSEcCtD
Gonadorelin—Vomiting—Etoposide—prostate cancer	2.35e-05	0.000537	CcSEcCtD
Gonadorelin—Erythema—Doxorubicin—prostate cancer	2.35e-05	0.000536	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—PTHLH—prostate cancer	2.35e-05	0.00249	CbGpPWpGaD
Gonadorelin—Headache—Etoposide—prostate cancer	2.32e-05	0.000529	CcSEcCtD
Gonadorelin—Flatulence—Doxorubicin—prostate cancer	2.32e-05	0.000528	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—PRKACB—prostate cancer	2.3e-05	0.00244	CbGpPWpGaD
Gonadorelin—Fatigue—Prednisone—prostate cancer	2.29e-05	0.000521	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—CALCA—prostate cancer	2.27e-05	0.00242	CbGpPWpGaD
Gonadorelin—Constipation—Prednisone—prostate cancer	2.27e-05	0.000517	CcSEcCtD
Gonadorelin—Hypersensitivity—Docetaxel—prostate cancer	2.27e-05	0.000517	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—PPP3CA—prostate cancer	2.24e-05	0.00238	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—CXCL12—prostate cancer	2.22e-05	0.00236	CbGpPWpGaD
Gonadorelin—Asthenia—Docetaxel—prostate cancer	2.21e-05	0.000503	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—ANXA1—prostate cancer	2.21e-05	0.00234	CbGpPWpGaD
Gonadorelin—Nausea—Etoposide—prostate cancer	2.2e-05	0.000501	CcSEcCtD
Gonadorelin—Hypersensitivity—Capecitabine—prostate cancer	2.19e-05	0.0005	CcSEcCtD
Gonadorelin—Pruritus—Docetaxel—prostate cancer	2.18e-05	0.000496	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Prednisone—prostate cancer	2.17e-05	0.000495	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—PENK—prostate cancer	2.15e-05	0.00228	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	2.14e-05	0.00227	CbGpPWpGaD
Gonadorelin—Asthenia—Capecitabine—prostate cancer	2.14e-05	0.000487	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—prostate cancer	2.11e-05	0.00224	CbGpPWpGaD
Gonadorelin—Pruritus—Capecitabine—prostate cancer	2.11e-05	0.00048	CcSEcCtD
Gonadorelin—Diarrhoea—Docetaxel—prostate cancer	2.1e-05	0.00048	CcSEcCtD
Gonadorelin—Abdominal pain—Prednisone—prostate cancer	2.1e-05	0.000478	CcSEcCtD
Gonadorelin—Anaphylactic shock—Epirubicin—prostate cancer	2.07e-05	0.000473	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—CALCA—prostate cancer	2.06e-05	0.00219	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GHR—prostate cancer	2.05e-05	0.00218	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—PIK3CA—prostate cancer	2.05e-05	0.00218	CbGpPWpGaD
Gonadorelin—Shock—Epirubicin—prostate cancer	2.04e-05	0.000465	CcSEcCtD
Gonadorelin—Diarrhoea—Capecitabine—prostate cancer	2.04e-05	0.000465	CcSEcCtD
Gonadorelin—Nervous system disorder—Epirubicin—prostate cancer	2.03e-05	0.000464	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—PRKCQ—prostate cancer	2.03e-05	0.00215	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—CXCL12—prostate cancer	2.02e-05	0.00214	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—prostate cancer	1.99e-05	0.00212	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NRP1—prostate cancer	1.97e-05	0.00209	CbGpPWpGaD
Gonadorelin—Vomiting—Docetaxel—prostate cancer	1.96e-05	0.000446	CcSEcCtD
Gonadorelin—Hypersensitivity—Prednisone—prostate cancer	1.95e-05	0.000446	CcSEcCtD
Gonadorelin—Headache—Docetaxel—prostate cancer	1.93e-05	0.000439	CcSEcCtD
Gonadorelin—Anaphylactic shock—Doxorubicin—prostate cancer	1.92e-05	0.000438	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—ADRB2—prostate cancer	1.91e-05	0.00202	CbGpPWpGaD
Gonadorelin—Asthenia—Prednisone—prostate cancer	1.9e-05	0.000434	CcSEcCtD
Gonadorelin—Vomiting—Capecitabine—prostate cancer	1.89e-05	0.000432	CcSEcCtD
Gonadorelin—Shock—Doxorubicin—prostate cancer	1.89e-05	0.000431	CcSEcCtD
Gonadorelin—Nervous system disorder—Doxorubicin—prostate cancer	1.88e-05	0.000429	CcSEcCtD
Gonadorelin—Pruritus—Prednisone—prostate cancer	1.88e-05	0.000428	CcSEcCtD
Gonadorelin—Headache—Capecitabine—prostate cancer	1.87e-05	0.000425	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—VAV3—prostate cancer	1.86e-05	0.00197	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PRKCQ—prostate cancer	1.84e-05	0.00196	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—prostate cancer	1.83e-05	0.00195	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—VIP—prostate cancer	1.83e-05	0.00194	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GNRH1—prostate cancer	1.83e-05	0.00194	CbGpPWpGaD
Gonadorelin—Nausea—Docetaxel—prostate cancer	1.83e-05	0.000417	CcSEcCtD
Gonadorelin—Diarrhoea—Prednisone—prostate cancer	1.81e-05	0.000414	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—ITPR1—prostate cancer	1.8e-05	0.00191	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Epirubicin—prostate cancer	1.79e-05	0.000408	CcSEcCtD
Gonadorelin—Fatigue—Epirubicin—prostate cancer	1.79e-05	0.000408	CcSEcCtD
Gonadorelin—Pain—Epirubicin—prostate cancer	1.77e-05	0.000404	CcSEcCtD
Gonadorelin—Constipation—Epirubicin—prostate cancer	1.77e-05	0.000404	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—LPAR1—prostate cancer	1.77e-05	0.00188	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GRP—prostate cancer	1.77e-05	0.00188	CbGpPWpGaD
Gonadorelin—Nausea—Capecitabine—prostate cancer	1.77e-05	0.000403	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—LRP2—prostate cancer	1.75e-05	0.00186	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PLCB2—prostate cancer	1.75e-05	0.00186	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—ADRB2—prostate cancer	1.73e-05	0.00184	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—P4HB—prostate cancer	1.72e-05	0.00183	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CX3CL1—prostate cancer	1.72e-05	0.00183	CbGpPWpGaD
Gonadorelin—Gastrointestinal pain—Epirubicin—prostate cancer	1.7e-05	0.000387	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—VAV3—prostate cancer	1.69e-05	0.00179	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HIST1H2BG—prostate cancer	1.69e-05	0.00179	CbGpPWpGaD
Gonadorelin—Vomiting—Prednisone—prostate cancer	1.69e-05	0.000385	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—GRB7—prostate cancer	1.67e-05	0.00178	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PDE4D—prostate cancer	1.67e-05	0.00178	CbGpPWpGaD
Gonadorelin—Headache—Prednisone—prostate cancer	1.66e-05	0.000379	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.66e-05	0.000378	CcSEcCtD
Gonadorelin—Fatigue—Doxorubicin—prostate cancer	1.65e-05	0.000377	CcSEcCtD
Gonadorelin—Constipation—Doxorubicin—prostate cancer	1.64e-05	0.000374	CcSEcCtD
Gonadorelin—Pain—Doxorubicin—prostate cancer	1.64e-05	0.000374	CcSEcCtD
Gonadorelin—Abdominal pain—Epirubicin—prostate cancer	1.64e-05	0.000374	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—ITPR1—prostate cancer	1.64e-05	0.00174	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HIST1H4H—prostate cancer	1.63e-05	0.00173	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CXCL8—prostate cancer	1.63e-05	0.00173	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—prostate cancer	1.62e-05	0.00172	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GNG5—prostate cancer	1.59e-05	0.00169	CbGpPWpGaD
Gonadorelin—Nausea—Prednisone—prostate cancer	1.58e-05	0.000359	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Doxorubicin—prostate cancer	1.57e-05	0.000358	CcSEcCtD
Gonadorelin—Hypersensitivity—Epirubicin—prostate cancer	1.53e-05	0.000348	CcSEcCtD
Gonadorelin—Abdominal pain—Doxorubicin—prostate cancer	1.52e-05	0.000346	CcSEcCtD
Gonadorelin—Asthenia—Epirubicin—prostate cancer	1.49e-05	0.000339	CcSEcCtD
Gonadorelin—Pruritus—Epirubicin—prostate cancer	1.47e-05	0.000335	CcSEcCtD
Gonadorelin—Diarrhoea—Epirubicin—prostate cancer	1.42e-05	0.000324	CcSEcCtD
Gonadorelin—Hypersensitivity—Doxorubicin—prostate cancer	1.41e-05	0.000322	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—PTHLH—prostate cancer	1.39e-05	0.00147	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TGFBR1—prostate cancer	1.39e-05	0.00147	CbGpPWpGaD
Gonadorelin—Asthenia—Doxorubicin—prostate cancer	1.38e-05	0.000314	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—AKR1C3—prostate cancer	1.36e-05	0.00145	CbGpPWpGaD
Gonadorelin—Pruritus—Doxorubicin—prostate cancer	1.36e-05	0.00031	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—PRKACB—prostate cancer	1.36e-05	0.00144	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—THBS1—prostate cancer	1.32e-05	0.0014	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PPP3CA—prostate cancer	1.32e-05	0.0014	CbGpPWpGaD
Gonadorelin—Vomiting—Epirubicin—prostate cancer	1.32e-05	0.000301	CcSEcCtD
Gonadorelin—Diarrhoea—Doxorubicin—prostate cancer	1.31e-05	0.000299	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—ANXA1—prostate cancer	1.3e-05	0.00138	CbGpPWpGaD
Gonadorelin—Headache—Epirubicin—prostate cancer	1.3e-05	0.000296	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—PRKCZ—prostate cancer	1.28e-05	0.00136	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3CG—prostate cancer	1.25e-05	0.00133	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FGFR4—prostate cancer	1.23e-05	0.00131	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PARP1—prostate cancer	1.23e-05	0.00131	CbGpPWpGaD
Gonadorelin—Nausea—Epirubicin—prostate cancer	1.23e-05	0.000281	CcSEcCtD
Gonadorelin—Vomiting—Doxorubicin—prostate cancer	1.22e-05	0.000278	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—CALCA—prostate cancer	1.22e-05	0.0013	CbGpPWpGaD
Gonadorelin—Headache—Doxorubicin—prostate cancer	1.2e-05	0.000274	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—CXCL12—prostate cancer	1.19e-05	0.00127	CbGpPWpGaD
Gonadorelin—Nausea—Doxorubicin—prostate cancer	1.14e-05	0.00026	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3CG—prostate cancer	1.13e-05	0.00121	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CASP9—prostate cancer	1.12e-05	0.00119	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3CD—prostate cancer	1.1e-05	0.00117	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PRKCQ—prostate cancer	1.09e-05	0.00115	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NGFR—prostate cancer	1.09e-05	0.00115	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MAP3K7—prostate cancer	1.07e-05	0.00114	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FGF10—prostate cancer	1.03e-05	0.0011	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ADRB2—prostate cancer	1.02e-05	0.00109	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—JAK2—prostate cancer	1.01e-05	0.00107	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—MAP2K1—prostate cancer	1e-05	0.00107	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3CD—prostate cancer	9.98e-06	0.00106	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—VAV3—prostate cancer	9.97e-06	0.00106	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TGFBR2—prostate cancer	9.83e-06	0.00104	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ITPR1—prostate cancer	9.67e-06	0.00103	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3CB—prostate cancer	9.58e-06	0.00102	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IGF1R—prostate cancer	9.24e-06	0.000982	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—CXCL8—prostate cancer	9.2e-06	0.000978	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—JAK2—prostate cancer	9.16e-06	0.000973	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—LPL—prostate cancer	8.86e-06	0.000942	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—IL2—prostate cancer	8.79e-06	0.000934	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PDGFRB—prostate cancer	8.78e-06	0.000933	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3CB—prostate cancer	8.7e-06	0.000924	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ITGB3—prostate cancer	8.56e-06	0.000909	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—CXCL8—prostate cancer	8.36e-06	0.000888	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ERBB3—prostate cancer	8.3e-06	0.000882	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FGFR2—prostate cancer	8.29e-06	0.000881	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—IL2—prostate cancer	7.99e-06	0.000848	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TERT—prostate cancer	7.96e-06	0.000845	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HIF1A—prostate cancer	7.61e-06	0.000808	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—LEP—prostate cancer	7.43e-06	0.000789	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CAV1—prostate cancer	7.36e-06	0.000782	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—KDR—prostate cancer	7.28e-06	0.000773	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ESR1—prostate cancer	7.09e-06	0.000753	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—BAD—prostate cancer	6.92e-06	0.000735	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3CG—prostate cancer	6.7e-06	0.000712	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—APC—prostate cancer	6.7e-06	0.000712	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—EGF—prostate cancer	6.63e-06	0.000704	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IRS1—prostate cancer	6.63e-06	0.000704	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GSK3B—prostate cancer	6.43e-06	0.000683	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—INS—prostate cancer	6.35e-06	0.000674	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CREBBP—prostate cancer	6.22e-06	0.00066	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IGF1—prostate cancer	6.14e-06	0.000652	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—EGFR—prostate cancer	6.11e-06	0.000649	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MAP2K1—prostate cancer	5.93e-06	0.00063	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3CD—prostate cancer	5.89e-06	0.000626	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3CA—prostate cancer	5.84e-06	0.00062	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SERPINE1—prostate cancer	5.83e-06	0.000619	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—KRAS—prostate cancer	5.77e-06	0.000613	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FGF2—prostate cancer	5.64e-06	0.0006	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NOS3—prostate cancer	5.57e-06	0.000591	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—JAK2—prostate cancer	5.41e-06	0.000575	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3CA—prostate cancer	5.3e-06	0.000563	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MDM2—prostate cancer	5.28e-06	0.000561	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ERBB2—prostate cancer	5.21e-06	0.000553	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3CB—prostate cancer	5.14e-06	0.000546	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CXCL8—prostate cancer	4.94e-06	0.000524	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CDKN1B—prostate cancer	4.82e-06	0.000512	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—AKT1—prostate cancer	4.77e-06	0.000507	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CASP3—prostate cancer	4.73e-06	0.000502	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IL2—prostate cancer	4.72e-06	0.000501	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—IL6—prostate cancer	4.69e-06	0.000499	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CCND1—prostate cancer	4.6e-06	0.000489	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CTNNB1—prostate cancer	4.55e-06	0.000484	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MMP9—prostate cancer	4.47e-06	0.000474	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CDKN1A—prostate cancer	4.45e-06	0.000473	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PTEN—prostate cancer	4.44e-06	0.000472	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—AKT1—prostate cancer	4.33e-06	0.00046	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—EP300—prostate cancer	4.23e-06	0.00045	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SRC—prostate cancer	4.12e-06	0.000437	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—VEGFA—prostate cancer	4.01e-06	0.000426	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—STAT3—prostate cancer	3.97e-06	0.000422	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MYC—prostate cancer	3.69e-06	0.000392	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TGFB1—prostate cancer	3.68e-06	0.000391	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—EGFR—prostate cancer	3.61e-06	0.000383	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—KRAS—prostate cancer	3.41e-06	0.000362	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3CA—prostate cancer	3.13e-06	0.000333	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TP53—prostate cancer	3.03e-06	0.000322	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IL6—prostate cancer	2.77e-06	0.000295	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—AKT1—prostate cancer	2.56e-06	0.000272	CbGpPWpGaD
